Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03955445
Other study ID # CLNP023B12001B
Secondary ID 2018-004253-24
Status Recruiting
Phase Phase 3
First received
Last updated
Start date October 3, 2019
Est. completion date December 1, 2028

Study information

Verified date January 2024
Source Novartis
Contact Novartis Pharmaceuticals
Phone 1-888-669-6682
Email novartis.email@novartis.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is an open-label extension study to evaluate the long-term efficacy, safety and tolerability of LNP023 in subjects with C3 glomerulopathy


Description:

The purpose of this extension study is to collect long-term efficacy, safety and tolerability data in eligible participants receiving open-label iptacopan after completing treatment in the C3 glomerulopathy (C3G) Phase II study CLNP023X2202 or the C3G Phase III study CLNP023B12301. Efficacy and safety assessments at the 9 month visit of this extension study in combination with data from CLNP023X2202 (baseline plus 3 months of treatment) afforded the opportunity to evaluate the effects of iptacopan on potential endpoint(s) for the Phase III trial in C3G at 12 months of treatment. In addition, the enrollment of participants from study CLNP023B12301 permits longer-term evaluation of the persistence of effects observed after 6 months (CLNP023B12301 patients randomised to placebo arm) or 12 months (CLNP023B12301 patients randomised to iptacopan arm) of iptacopan treatment. These longer term efficacy assessments may be compared to historical/concurrent control data available from relevant real world databases in C3G patients and used as supportive information for registration purposes. The extension study is expected to continue until the drug product becomes commercially available and accessible (anticipated to be up to approximately 66 months), or the benefit-risk profile is no longer positive, or the program is discontinued for business or strategic reasons. Study CLNP023X2202 has enrolled C3G patients with native kidney disease (Cohort A) and C3G patients who have undergone kidney transplant and have recurrence of C3G (Cohort B); CLNP023B12301 will only enroll patients with native kidneys. "Baseline" refers to the Day 1 visit (pre-dose) of CLNP023X2202 or CLNP023B12301, whereas the Day 1 visit for this C3G extension study (CLNP023B12001B) is identified as "Extension Day 1".


Recruitment information / eligibility

Status Recruiting
Enrollment 94
Est. completion date December 1, 2028
Est. primary completion date October 31, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Patients must have completed the treatment period of the CLNP023X2202 or CLNP023B12301 trial on study drug Exclusion Criteria: - Severe concurrent co-morbidities, e.g. advanced cardiac disease (NYHA class IV), severe pulmonary arterial hypertension (WHO class IV), or any illness or medical condition that in the opinion of the investigator and sponsor is likely to prevent the patient from safely tolerating LNP023 or complying with the requirements of the study - Participants with an active systemic bacterial, viral or fungal infection within 14 days prior to screening, or the presence of fever = 38oC (100.4oF) within 7 days prior to screening. - History or current diagnosis of ECG abnormalities indicating significant risk of safety for subjects - History of HIV or any other immunodeficiency disease

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
LNP023
LNP023 capsules

Locations

Country Name City State
Argentina Novartis Investigative Site Buenos Aires
Brazil Novartis Investigative Site São Paulo SP
China Novartis Investigative Site Beijing
China Novartis Investigative Site Shanghai
France Novartis Investigative Site Montpellier
France Novartis Investigative Site Paris
Germany Novartis Investigative Site Erlangen
Germany Novartis Investigative Site Essen
Greece Novartis Investigative Site Heraklion Crete
Israel Novartis Investigative Site Petach Tikva
Israel Novartis Investigative Site Petach-Tikva
Italy Novartis Investigative Site Ranica BG
Italy Novartis Investigative Site Roma RM
Japan Novartis Investigative Site Asahikawa-city Hokkaido
Japan Novartis Investigative Site Nagoya Aichi
Japan Novartis Investigative Site Sapporo Hokkaido
Netherlands Novartis Investigative Site Leiden Zuid-Holland
Spain Novartis Investigative Site Barcelona Catalunya
Spain Novartis Investigative Site Madrid
Switzerland Novartis Investigative Site Bern
Turkey Novartis Investigative Site Ankara
United Kingdom Novartis Investigative Site London
United Kingdom Novartis Investigative Site Newcastle Upon Tyne
United States Novartis Investigative Site Iowa City Iowa
United States Novartis Investigative Site Lawrenceville Georgia
United States Novartis Investigative Site New York New York

Sponsors (1)

Lead Sponsor Collaborator
Novartis Pharmaceuticals

Countries where clinical trial is conducted

United States,  Argentina,  Brazil,  China,  France,  Germany,  Greece,  Israel,  Italy,  Japan,  Netherlands,  Spain,  Switzerland,  Turkey,  United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary CLNP023X2202 Cohort A-native C3G: Number of participants who achieve the composite renal endpoint A participant meets the requirements of the composite renal endpoint if they satisfy the following criteria at the 9-month visit in CLNP023B12001B: (1) a stable or improved eGFR compared to the baseline visit in CLNP023X2202 (=10% reduction in eGFR), and (2) either =50% reduction compared to the baseline visit in CLNP023X2202 or a reduction to <300 mg/g in UPCR and (3) either a =50% increase in C3 compared to baseline or an increase to =90 mg/dL (i.e., = the lower limit of normal (LLN)). Initiation of treatment with eculizumab or any other complement pathway modifying agent automatically designates the participant as not meeting the endpoint. 9-month visit
Primary CLNP023X2202 Cohort B - kidney transplant and recurrent C3G: Change from baseline in the C3 Deposit Score Change from baseline in the C3 Deposit Score (based on immunofluorescence microscopy) compared to baseline in the CLNP023X2202 study. 6 - to 9- month visit
Primary Number of AEs of special interest Number of participants with AEs of special interest will be collected to evaluate the long-term safety and tolerability of iptacopan in participants with C3G Up to 66 months for participants from CLNP023X2202 and up to 36 months for participants from CLNP023B12301
Primary Number of participants with study drug discontinuation due to an AE (or any safety issue) Number of participants with study drug discontinuation due to an AE to evaluate the long-term safety and tolerability of iptacopan in participants with C3G Up to 66 months for participants from CLNP023X2202 and up to 36 months for participants from CLNP023B12301
Primary Number of participants with abnormal clinically significant vital signs,ECGs, and safety laboratory measurements Number of participants with abnormal clinically significant vital signs, ECGs, and safety laboratory measurements to evaluate the long-term safety and tolerability of iptacopan in participants with C3G Up to 66 months for participants from CLNP023X2202 and up to 36 months for participants from CLNP023B12301
Secondary CLNP023X2202: Number of participants who achieve the 2-component composite renal endpoint A participant is defined as achieving the composite renal endpoint if they meet the following criteria at the 9-month visit in CLNP023B12001B: (1) a stable or improved eGFR compared to the baseline visit in CLNP023X2202 (=10% reduction in eGFR), and (2) either =50% reduction compared to the baseline visit in CLNP023X2202 or a reduction to <300 mg/g in UPCR.
Initiation of treatment with eculizumab or any other complement pathway modifying agent automatically designates the participant as a not meeting the composite renal endpoint.
9-month visit
Secondary CLNP023X2202: Change from baseline in log-transformed urine protein/creatinine ratio (UPCR) Long-term effect of LNP023 on renal function in C3G subjects by assessing the change from baseline in log-transformed urine protein/creatinine ratio (UPCR) 3 month visit, 9-month visit and up to 66 months
Secondary CLNP023X2202: Change from baseline in log-transformed urine albumin/creatinine ratio (UACR) Long-term effect of LNP023 on renal function in C3G subjects by assessing the change from baseline in log-transformed urine albumin/creatinine ratio (UACR) 3 month visit, 9-month visit and up to 66 months
Secondary CLNP023X2202: Change from baseline in serum creatinine concentration Long-term effect of LNP023 on renal function in C3G subjects by assessing the change in serum creatinine at 9 months visit compared to CLNP023X2202 baseline 9-month visit and up to 66 months
Secondary CLNP023X2202: Change from baseline in estimated glomerular filtration rate (eGFR) Long-term effect of LNP023 on renal function in C3G subjects by assessing the change in eGFR at 9 months visit compared to CLNP023X2202 baseline 9-month visit and up to 66 months
Secondary CLNP023X2202: Status of C3G disease progression Describe the status of C3G disease progression based on glomerular histopathology in a renal biopsy at 6 to 9 months from entry to the study compared to those obtained prior to treatment in the CLNP023X2202 study 6 to 9 month visit
Secondary CLNP023X2202: Log-transformed ratio to baseline in serum C3 Long-term effect of LNP023 on son C3 at the 9-month visit by evaluating the Log-transformed ratio to baseline in serum C3 9-month visit and up to 66 months
Secondary CLNP023X2202: Number of participants who achieve the composite renal endpoint A participant is defined as achieving the composite renal endpoint if they meet the following criteria at times >9 months in CLNP023B12001B: (1) a stable or improved eGFR compared to the baseline visit in CLNP023X2202 (=10% reduction in eGFR), and (2) either =50% reduction compared to the baseline visit in CLNP023X2202 or a reduction to <300 mg/g in UPCR and (3) either a =50% increase in C3 compared to baseline or an increase to =90 mg/dL (i.e., LLN). Initiation of treatment with eculizumab or any other complement pathway modifying agent automatically designates the participant as a not meeting the composite renal endpoint. Up to 66 months
Secondary CLNP023X2202: Plasma LNP023 concentration up to 12 months at trough Measurement of LNP023 plasma concentration to evaluate the pharmacokinetics of iptacopan in participants with prolonged treatment 3-months, 6-months, 9-months and 12-months visits
Secondary CLNP023B12301: Change from baseline in log-transformed UPCR over time by treatment groups Change from baseline in log-transformed UPCR will be assessed to evaluate the long-term effect of iptacopan on proteinuria Up to 36 months
Secondary CLNP023B12301: Change from Day 180 in log-transformed UPCR over time (placebo arm of study CLNP023B12301) Change from Day 180 in study CLNP023B12301 in log transformed UPCR will be assessed to evaluate the long-term effect of iptacopan on proteinuria Up to 36 months
Secondary CLNP023B12301: Change from baseline in eGFR over time Change from baseline in eGFR will be assessed to evaluate the long-term effect of iptacopan on eGFR Up to 36 months
Secondary CLNP023B12301: Change from Day 180 in study CLNP023B12301 in eGFR over time (placebo arm of study CLNP023B12301) Change in eGFR over time will be assessed to evaluate the long-term effect of iptacopan on eGFR Up to 36 months
Secondary CLNP023B12301: Number of participants who achieve a 2-component composite renal endpoint A participant is defined as meeting the requirements of the composite renal endpoint if they satisfy the eGFR (a stable or improved eGFR, i.e., =15% reduction in eGFR compared to the baseline visit) and UPCR (=50% reduction in UPCR compared to the baseline visit) criteria assessed at a visit. The rate will be evaluated over time. Up to 36 months
See also
  Status Clinical Trial Phase
Recruiting NCT04183101 - Evaluation of a Renin Inhibitor, Aliskiren, Compared to Enalapril, in C3 Glomerulopathy Phase 2
Recruiting NCT06065852 - National Registry of Rare Kidney Diseases
Not yet recruiting NCT05647811 - Study of NM8074 in Adult C3 Glomerulopathy Patients Phase 1/Phase 2
Active, not recruiting NCT05067127 - Phase III Study Assessing the Efficacy and Safety of Pegcetacoplan in Patients With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis Phase 3
Active, not recruiting NCT05809531 - An Open-Label, Nonrandomized, Multicenter Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan in Participants With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis Phase 3
Recruiting NCT06209736 - Safety and Efficacy Study of OMS906 in Patients With C3G and ICGN Phase 2
Terminated NCT03459443 - A Proof of Concept Study for a 12 Month Treatment in Patients With C3G or IC-MPGN Treated With ACH-0144471 Phase 2
Completed NCT03369236 - A Proof-of-Concept Study of Danicopan for 6 Months of Treatment in Participants With C3 Glomerulopathy (C3G) Phase 2
Active, not recruiting NCT04572854 - Study Assessing the Safety and Efficacy of Pegcetacoplan in Post-Transplant Recurrence of C3G or IC-MPGN Phase 2
Recruiting NCT02682407 - Safety Study of IgAN, LN, MN, & C3 Glomerulopathy Including Dense Deposit Disease Treated With OMS721 Phase 2
Recruiting NCT05083364 - Study of ARO-C3 in Adult Healthy Volunteers and Patients With Complement Mediated Renal Disease Phase 1
Completed NCT03723512 - Non-contrast Enhanced MRI in Patients With C3 Glomerulopathy (C3G) or Immune-complex Membranoproliferative Glomerulonephritis (IC-MPGN) Enrolled in the ACH471-205 Study N/A
Completed NCT03124368 - A Proof-of-Mechanism Study to Determine the Effect of Danicopan on C3 Levels in Participants With C3G or IC-MPGN Phase 2
Available NCT04729062 - C3G/Primary IC-MPGN EAP